Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lolli

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Diabetes|December 1, 1984
Demonstration of a dawn phenomenon in normal human volunteersG B Bolli, P De Feo, S De Cosmo, et al.
Endoscopy|March 26, 2009
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinibM Saponara, M Di Battista, C Lolli, et al.
Scientific Reports|May 5, 2022
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancerM C Cursano, V Conteduca, E Scarpi, et al.
ESMO Open|October 22, 2023
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trialN Brighi, V Conteduca, G Gurioli, et al.
Scientific Reports|November 16, 2017
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancerV Conteduca, E Scarpi, P Caroli, et al.
ESMO Open|April 25, 2025
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trialG Schepisi, M Urbini, C Casadei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker studyV Conteduca, D Wetterskog, M T A Sharabiani, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Diabetes|December 1, 1984
Demonstration of a dawn phenomenon in normal human volunteersG B Bolli, P De Feo, S De Cosmo, et al.
Endoscopy|March 26, 2009
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinibM Saponara, M Di Battista, C Lolli, et al.
Scientific Reports|May 5, 2022
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancerM C Cursano, V Conteduca, E Scarpi, et al.
ESMO Open|October 22, 2023
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trialN Brighi, V Conteduca, G Gurioli, et al.
Scientific Reports|November 16, 2017
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancerV Conteduca, E Scarpi, P Caroli, et al.
ESMO Open|April 25, 2025
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trialG Schepisi, M Urbini, C Casadei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker studyV Conteduca, D Wetterskog, M T A Sharabiani, et al.
Pageof 3